Gilead Sciences Is Still Undervalued
Summary
- Gilead Sciences’ stock price has increase over 19% so far this year due to its extremely successful hepatitis C drug solutions.
- There is some concern about sales growth for these drugs going forward, but they are overblown.
- There is upside potential for the stock in the hepatitis B market, made evident by recent events.